Interferon alpha2b inhibits the murine melanoma cell line Cloudman S91 in vivo but not in vitro: a model for studying tumor cell-cytokine interactions

Habib, Fahim A.; Lobocki, Catherine; Ezhuthachan, Rutu; Chelladurai, Mohan; Preventza, Ourania; Mittal, Vijay K.; Habib, F A; Lobocki, C; Ezhuthachan, R; Chelladurai, M; Preventza, O; Mittal, V K
March 2001
American Surgeon;Mar2001, Vol. 67 Issue 3, p257
Academic Journal
journal article
Interferon alpha2b has recently been shown to improve outcome in patients with metastatic malignant melanoma. The high-dose interferon therapy used is however associated with significant systemic adverse effects. These adverse effects are likely related to the multitude of actions of interferon which in addition to its antineoplastic effects also possesses antiviral and immunomodulating properties. Elucidation of the mechanism of the antiproliferative effects of interferon may allow for the development of agents that possess the antineoplastic properties while being devoid of the other effects that make interferon toxic. In the animal model developed for this study tumors in mice receiving interferon alpha2b grew at a slower rate and achieved a small final tumor volume (3040 +/- 690 vs 1400 +/- 314 mm3 for the control and treated groups respectively, P < 0.05). Furthermore the final tumor weight in the treated group was significantly smaller (1.50 +/- 0.21 g vs 2.76 +/- 0.46 g for the treated and control groups respectively; P = 0.036). The (3-[4,5-Dimethylthiazol-2-y]-2,5-diphenyltetrazolium bromide) (MTT) colorimetric assay failed to reveal any direct effects of interferon alpha2b on this murine melanoma cell line. This antiproliferative effect of interferon alpha2b was in addition found to be independent of alterations in the expression of the angiogenic cytokines vascular endothelial growth factor, basic fibroblast growth factor, and transforming growth factor beta.


Related Articles

  • Adjuvant interferon in the treatment of melanoma – reply. Middleton, M R // British Journal of Cancer;5/15/2000, Vol. 82 Issue 10, p1755 

    Presents a response to the editorial by M.R. Middleton regarding the first analysis of the intergroup E1690 trial of high and low dose interferon for high risk melanoma conducted in the U.S. between 1990 and 1995 published in the 2002 issue of 'British Journal of Cancer.' Differences in the...

  • Adjuvant interferon in the treatment of melanoma. Kirkwood, J M // British Journal of Cancer;5/15/2000, Vol. 82 Issue 10, p1755 

    Presents views of the author on comments by J.M. Kirkwood on the editorial regarding analysis of intergroup E1690 trial of interferon for high risk melanoma conducted in the U.S. between 1990 and 1995 published in the 2002 issue of 'British Journal of Cancer.' Improvement in overall survival...

  • Interferon-α-2b.  // Reactions Weekly;10/20/2012, Issue 1424, p32 

    The article describes the case of a 35-year-old male patient who developed Meyerson's phenomenon during treatment with interferon α-2b for high-risk melanoma.

  • Adjuvant interferon in the treatment of melanoma. Middleton, M R // British Journal of Cancer;8/1/99, Vol. 80 Issue 11, p1679 

    Editorial. Focuses on the use of high-dose interferon for the treatment of resected melanoma. Studies conducted to check the efficacy of high-dose interferon and low-dose interferon; Difference in the results of two studies; Uncertainties related to the use of high-dose interferon for the...

  • Reply: Value of tyrosinase RT-PCR in melanoma prognosis. Gogas, H // British Journal of Cancer;3/24/2003, Vol. 88 Issue 6, p982 

    British Journal of Cancer (2003) 88, 982. doi:10.1038/sj.bjc.6600835 www.bjcancer.com

  • Erratum.  // Oncology;Jul2012, Vol. 83 Issue 2, p359 

    A correction to the article "Sequential Local Injection of Low-Dose Interfreron-Beta for Maintenance Therapy in Stage II and Stage III Melanoma: A Single-Institution Matched Case-Control Study," by S. Aoyagi et al. in the issue 2012;82:139-145 is presented.

  • Study shows low-dose interferon ineffective against metastatic melanoma. Moyer, Paula // Dermatology Times;Jul2002, Vol. 23 Issue 7, p31 

    Examines the efficacy of adjuvant low-dose interferon against metastatic melanoma. Survival rates of stage III melanoma patients; Metastasis of regional lymph nodes; Pharmacokinetics of interferon.

  • Is There a Role for Adjuvant High-Dose Interferon-α-2b in the Management of Melanoma? Sabel, Michael S.; Sondak, Vernon K. // Drugs;2003, Vol. 63 Issue 11, p1053 

    The knowledge that melanoma is susceptible to attack by the host's immune system has resulted in the testing of a variety of immunotherapies. Interferon-α-2b, which has several anti-tumour mechanisms including an antiproliferative effect, an anti-angiogenesis effect, the enhancement of...

  • Regimen, patient candidates factors for low-dose IFNa use. Guttman, Cheryl // Dermatology Times;Mar2001, Vol. 22 Issue 3, p34 

    Reports on the use of low-dose interferon as adjuvant therapy for malignant melanoma. Value of prolonging treatment duration; Identification of appropriate candidates.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics